Scholars Central

OtherPublished 26 Jul 2016

Adalimumab for the treatment of rheumatoid arthritis

Authors: Susan J Lee, Arthur Kavanaugh

Clinical Practice

Volume 2 · Issue 1 · Pages 13

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Rheumatoid arthritis is a chronic, inflammatory condition of unknown etiology, affecting about 1% of the general population. Adalimumab was added to our armamentarium against rheumatoid arthritis in December 2002. It can be used either alone or in combination with methotrexate in those patients who continue to have persistent disease activity despite their therapy. Adalimumab has been shown to rapidly improve the clinical status and retard radiographic progression in a substantial number of treated patients. Its clinical efficacy has been shown to be sustained through several years of continued therapy. The rate of adverse events is comparable to that of other tumor necrosis factor inhibitors. As with those agents, while infections are the main adverse event clinicians should be aware of, patients should also be counseled about, and monitored for, rare events such as tuberculosis, opportunistic infections, lymphoma, and demyelinating or autoimmune diseases.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Practice.

All its articles

Article · 28 Mar 2025

Using

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Susan J Lee”
  • BylineArticles whose byline prints “Arthur Kavanaugh”